The medical device industry witnessed a transformative milestone on December 5, 2024, as Lungpacer Medical secured premarket approval from the U.S. Food and Drug Administration for its flagship AeroPace System. This Lungpacer approval represents the first FDA clearance for a temporary diaphragm activation system designed to improve ventilator weaning success in critically ill patients.
The Exton, Pennsylvania-based neurostimulation company developed the AeroPace System to address a critical challenge facing intensive care units nationwide: ventilator-induced diaphragm dysfunction. When patients remain on mechanical ventilation for extended periods, the diaphragm muscle becomes inactive and weakens significantly, creating substantial barriers to successful weaning from breathing support.
Lungpacer Approval Addresses Critical Healthcare Gap
The FDA-approved indication allows the AeroPace System to improve weaning success by increasing weaning rates, reducing ventilator days, and decreasing reintubation in patients aged 18 years or older who have been on mechanical ventilation for at least 96 hours without successful weaning. This Lungpacer approval fills a significant void in respiratory care, as no therapeutic treatment previously existed to strengthen the diaphragm during mechanical ventilation.
The neurostimulation system works through an electrode-containing cardiovascular catheter paired with sophisticated software-controlled technology. It delivers periodic phrenic nerve stimulation through the venous catheter, contracting and strengthening the diaphragm in mechanically ventilated patients. The minimally invasive transvenous approach represents a paradigm shift in critical care management.
Clinical Evidence Supporting FDA Breakthrough Device
Lungpacer Medical built an extensive evidence portfolio supporting this landmark approval, including more than 100 scientific presentations, 30 peer-reviewed publications, and clinical studies involving over 400 patients at 50 international centers. The company’s research demonstrates that approximately 2.5 million mechanically ventilated critical care patients in the United States could potentially benefit from this technology.
Clinical evaluations revealed compelling outcomes that influenced the approval decision. The AeroPace therapy demonstrated that more patients successfully weaned from ventilation, with the risk of remaining on mechanical ventilation at 30 days reduced by up to 37 percent. Weaning speed accelerated by nearly three days compared to standard care protocols. Perhaps most significantly, the risk of reintubation at 30 days decreased by up to 60 percent, addressing a major complication that extends hospital stays and increases healthcare costs.
Leadership Vision Drives Company Mission
Doug Evans, president and chief executive officer of Lungpacer Medical, brings a deeply personal motivation to this achievement. His son Cameron endured the challenges of mechanical ventilation before passing away in 2012, an experience that ultimately led Evans to accept the company’s leadership role in 2014.
“Today’s approval of our AeroPace System, an FDA designated Breakthrough Device, is transformative for respiratory care and represents a new era in which clinicians will now have a treatment option for critical care patients who have failed to wean from mechanical ventilation,” Evans stated following the announcement.
Evans is an accomplished medical device executive with 30 years of industry experience and holds over 200 issued patents covering dozens of devices used by more than 15 million patients worldwide. He previously served as chief operating officer and board member of Kensey Nash Corporation, which was acquired by Royal DSM for $360 million in 2012.
Healthcare System Impact and Market Implications
The economic implications of this technology extend beyond immediate patienat care. Mechanical ventilation accounts for up to $96 billion annually in direct care costs across the United States healthcare system. By reducing ventilator days and reintubation rates, the AeroPace System could significantly decrease the healthcare administration burden while improving patient outcomes.
Richard Branson, professor at the University of Cincinnati, emphasized the treatment gap that existed before this approval: “To date, alterations in ventilator settings and patient monitoring can aid in limiting diaphragmatic injury and myopathy, but there are no therapeutic treatments. Diaphragmatic pacing using AeroPace therapy is the first approved intervention proven to shorten the liberation process.”
The AeroPace System previously received FDA Breakthrough Device designation in May 2016 and Emergency Use Authorization in April 2020 during the COVID-19 pandemic, when mechanical ventilation demand surged globally. The December 2024 premarket approval transitions the device from emergency use to full commercial availability.
Pipeline Development and Future Innovations
Lungpacer Medical continues advancing its investigational AeroNova System, currently in clinical trials. This second-generation technology utilizes continual diaphragm stimulation in synchrony with mechanical ventilation and is designed to achieve physiological breathing patterns intended to mitigate multi-organ ventilator-induced injury affecting the lung, diaphragm, heart, and brain.
Together, the AeroPace and AeroNova systems address the comprehensive needs of mechanically ventilated patients, from preventing diaphragm atrophy during ventilation to facilitating faster liberation from breathing support. The company maintains an extensive patent portfolio protecting its diaphragm pacing therapy innovations.
The standard of care for mechanically ventilated patients has remained largely unchanged for decades, relying primarily on daily spontaneous breathing trials and careful monitoring. These trials prove stressful for patients and must often be repeated over multiple days. Clinicians now have an active intervention that strengthens the diaphragm rather than simply waiting for natural recovery.
Lungpacer Medical’s headquarters in Exton positions the company within Pennsylvania’s thriving medical technology corridor. The firm operates with a dedicated team of clinical and engineering experts who have collectively contributed to the development of both the approved AeroPace System and the investigational pipeline products.
The approval arrives as healthcare systems continue seeking innovations that reduce intensive care unit length of stay while improving patient quality of life. Extended mechanical ventilation correlates with increased complications, including pneumonia, sepsis, and long-term disability. Technologies that accelerate safe ventilator liberation therefore deliver value across multiple dimensions of care delivery.
Industry observers note that the neurostimulation approach represents a fundamentally different strategy than previous attempts to address diaphragm weakness. Rather than modifying ventilator settings or pharmaceutical interventions, the AeroPace System directly targets the underlying problem by actively exercising and strengthening the diaphragm muscle through controlled electrical stimulation.
